{"entity":{"id":"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012","kind":"paper","name":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","aka":[],"tldr":"Three years of imatinib after surgery for high-risk gastrointestinal stromal tumour reduced recurrences and deaths compared with one year, setting the standard duration of adjuvant therapy.","summary":"Phase 3 trial of 400 patients with resected KIT-positive GIST at high risk of recurrence randomised to 12 or 36 months of adjuvant imatinib 400 mg daily.\n\nFive-year recurrence-free survival was 65.6 versus 47.9 percent (hazard ratio 0.46) and five-year overall survival 92.0 versus 81.7 percent (hazard ratio 0.45); ten-year follow-up confirmed the survival benefit, and discontinuation for adverse events was more common with longer treatment.","asOf":"2026-09-17","links":[{"label":"JAMA 2012","url":"https://doi.org/10.1001/jama.2012.347"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/22453568/"}],"tags":[],"related":[],"cancers":["gist-kit-exon-11"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama"],"dependsOn":[],"notes":[],"journal":"JAMA","year":2012,"doi":"10.1001/jama.2012.347","pmid":"22453568","authors":"Joensuu H, Eriksson M, Sundby Hall K, et al.","paperType":"rct","findings":["Five-year recurrence-free survival 65.6 percent vs 47.9 percent; hazard ratio 0.46.","Five-year overall survival 92.0 percent vs 81.7 percent; hazard ratio 0.45."],"whatItMeans":"Three years of adjuvant imatinib is standard for high-risk resected GIST with imatinib-sensitive mutations; longer courses are being tested.","caveats":["Patients with PDGFRA D842V mutations, which are imatinib-resistant, do not benefit.","Recurrences resume after imatinib is stopped."],"changedPractice":true,"participants":400},"route":"/key-papers/paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012/","neighbours":{"cancer":[{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"journal":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/"}]}}